A study appearing April 14 in the journal Neuron suggests there may be a new way to change the damaging course of Huntington disease. University of California, Irvine neurobiologists Leslie Thompson and Joseph Ochaba with the Departments of Neurobiology & Behavior and Psychiatry & Human Behavior and their colleagues from UCI and from Children's Hospital of Philadelphia have shown that reducing the aberrant accumulation of a particular form of the mutant Huntingtin protein corresponds to improvement in symptoms and neuroinflammation in HD mice. They showed this by targeting and modulating levels of PIAS1 - a protein implicated in cancer and other diseases - which they found led to the reduction of the mutant Huntington protein. The work suggests that changing levels of the PIAS1 protein and targeting this pathway could have a benefit to disease. There are no current treatments for HD, although Thompson's ongoing work with stem cell-based therapies are showing promise.
Targeted degradation of Pin1 shows promise for pancreatic cancer treatment